C4 Therapeutics, Inc. (CCCC) is a clinical-stage biopharmaceutical company focused on targeted protein degradation for cancer and other difficult-to-treat diseases. The stock has been rebuilding momentum after a multiyear drawdown, and investors are now asking a specific question: can CCCC reach $7 per share?
The $7 level is not an arbitrary round number. It sits near the low end of Wall Street’s published 12-month price targets for the stock and represents the first major technical objective above the stock’s recent peak of $5.17. Because CCCC has spent much of the past year recovering from a low of $1.69, a move to $7 would confirm that the market is treating the company as a credible late-stage oncology story rather than a speculative micro-cap.
C4 Therapeutics develops medicines that use the body’s natural protein-recycling system to degrade disease-causing proteins. Its lead program, cemsidomide, is an oral degrader targeting IKZF1/3 proteins in relapsed/refractory multiple myeloma. The company is enrolling the Phase 2 MOMENTUM trial, with initial response-rate data expected in the second half of 2027, and is also testing cemsidomide in combination with elranatamab in a Phase 1b study.
Financially, the company remains pre-profit. Second-quarter 2026 revenue was $6.6 million, with a net loss of $23.6 million. However, cash, cash equivalents and marketable securities stood at approximately $300.4 million as of June 30, 2026, which management expects will fund operations into 2028. The company also received a $20 million upfront payment from Roche in May 2026 under a degrader-antibody conjugate collaboration.
The strongest argument for a move toward $7 is that several Wall Street firms already value the stock at or above that level. Barclays and Guggenheim have published $7 targets, while Wells Fargo, Jefferies and others have targets ranging from $10 to $14. That suggests professional analysts are pricing in meaningful clinical and partnership upside that the current share price does not yet fully reflect.
The Roche collaboration also provides external validation of C4 Therapeutics’ platform and a source of non-dilutive funding. Combined with a cash runway into 2028, this reduces the near-term risk of a forced capital raise. In addition, reported short interest near 23% of the float as of mid-July 2026 could amplify an upward move if positive news forces short sellers to cover.
The central risk is clinical. Cemsidomide is still in Phase 2, and the next major efficacy readout is not expected until the second half of 2027. Until then, the stock may lack the kind of binary, data-driven catalyst that typically powers large biotech re-ratings.
The company also remains deeply unprofitable, with revenue expected to decline in 2026 as collaboration payments fluctuate. During the second quarter, C4 Therapeutics raised approximately $33.5 million through its at-the-market program, a reminder that equity dilution remains an ongoing possibility. Finally, the stock must first break decisively above its 52-week high of $5.17, a level that has already marked the upper boundary of the recent recovery.
Analyst opinion is broadly constructive but varies widely. Depending on the data provider, the consensus 12-month stock price target ranges from about $7.75 to $13.33, with individual targets stretching from $6 or $7 on the low end to $30 on the high end. The dispersion reflects genuine uncertainty about the value of a clinical-stage platform.
From a technical analysis perspective, the stock has established support in the $3.40–$3.50 zone during recent consolidation. The first major resistance level is the 52-week high near $5.17. A decisive close above that level would open the path toward $7, while failure to hold current support would keep the stock rangebound.
For traders monitoring CCCC and similar setups, Tickeron’s AI Daily Buy/Sell Signals provide a data-driven way to track changing market conditions. The product uses artificial intelligence to continuously monitor thousands of stocks and ETFs and generate Buy, Sell, or Hold signals based on technical behavior and AI-driven analysis. Traders can use these signals to discover new opportunities, monitor existing positions, and identify shifting market trends more efficiently. Exploring AI-generated signals may help investors complement their own research when evaluating whether a move toward a key price level is gaining traction.
A move to $7 appears achievable over a 12-to-24-month horizon, but it is not a near-term certainty. The strongest supporting factors are a multiyear cash runway, analyst targets at or above $7, and the validation provided by the Roche collaboration. The primary risks are binary clinical outcomes, limited catalysts before 2027, ongoing losses, and potential dilution. Investors should monitor cemsidomide trial progress, partnership milestones, and the stock’s ability to hold support near $3.40–$3.50 before challenging the $5.17 resistance level.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, CCCC has been loosely correlated with AXON. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if CCCC jumps, then AXON could also see price increases.
| Ticker / NAME | Correlation To CCCC | 1D Price Change % | ||
|---|---|---|---|---|
| CCCC | 100% | -0.74% | ||
| AXON - CCCC | 40% Loosely correlated | +2.20% | ||
| SVRA - CCCC | 38% Loosely correlated | +1.82% | ||
| GLUE - CCCC | 36% Loosely correlated | -3.25% | ||
| REPL - CCCC | 35% Loosely correlated | +5.12% | ||
| WVE - CCCC | 35% Loosely correlated | +0.76% | ||
More | ||||